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BACKGROUND: A dilemma faced by health-care administrators is that need greatly outstrips
capacity for diagnosing and treating sleep apnea, with such decisions carrying significant economic
consequences. Our objective was to develop an economic model to estimate the relative costs of 4
approaches for diagnosis and initial treatment of sleep apnea. METHODS: The analysis consisted
of developing a mathematical model depicting possible diagnostic and treatment approaches to the
care of patients with sleep apnea; developing 4 clinical scenarios to describe distinct approaches to
the management of sleep apnea patients (in-laboratory, unattended, direct-to-autotitrating PAP
[auto-PAP], and mixed); and identifying costs associated with each scenario. We created a hypo-
thetical cohort of 1,000 patients with 85% prevalence of sleep apnea to generate cost estimates.
RESULTS: The driver of per-patient costs was the total number of sleep studies, which varied
widely across scenarios: from 425 for the direct-to-auto-PAP approach to 1,441 in the unattended
approach. The scenarios also differed in per-patient costs: Per-patient costs excluding facility
startup costs were $456 for direct-to-auto-PAP, $913 for in-laboratory, $991 for mixed, and $1,090
for unattended. CONCLUSIONS: Approaches to diagnosing and treating sleep apnea that empha-
sized early application of auto-PAP had lower per-patient costs. Key words: sleep apnea; economic
model; health-care capacity; positive airway pressure; unattended polysomnography; health services
research. [Respir Care 2018;63(1):50–61. © 2018 Daedalus Enterprises]
Introduction
Health-care administrators and policymakers face a ba-
sic dilemma when identifying patients with sleep apnea:
Need greatly outstrips capacity. Sleep apnea is a com-
monly recognized medical problem in the United States,
yet an estimated 70–80% of patients with the condition
remain undiagnosed.1-4 Because sleep apnea is associated
with a variety of poor patient outcomes,5,6 awareness of
the importance of diagnosing sleep apnea has become much
more common in recent years, with referrals for polysom-
nography, the accepted standard method for diagnosing
sleep apnea, increasing 12-fold worldwide over the past
decade.1 Sleep laboratory capacity has not accompanied
the dramatic increase in demand, contributing to wide-
spread underdiagnosis and undertreatment of sleep apnea.7
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The Veterans Health Administration (VA), the single
largest health-care provider in the United States, provides
a large-scale example of the tremendous challenges asso-
ciated with the diagnosis of obstructive sleep apnea (OSA).
The VA estimates that 1.5 million veterans have OSA, yet
in 2001, there were only 148 beds in VA sleep laboratories
across the United States serving a total of about 6,000
patients.8,9 Of the total number of patients with OSA in the
general veteran population, an estimated 95% of veterans
with OSA remain undiagnosed.10
This disparity between need and capacity is particularly
striking within the VA because the prevalence of OSA
among veterans is approximately 4-fold higher than in the
general United States population.10 This is because factors
associated with OSA, such as older age, obesity, male sex,
and alcohol use are all relatively common within the VA
patient population.10 Given the bottleneck of inadequate
capacity in existing sleep laboratories, additional ap-
proaches to diagnosing and treating OSA may need to be
implemented, specifically approaches that are accurate,
cost-efficient, and scalable. We sought to construct an eco-
nomic model to estimate the costs of building sleep med-
icine programs for the diagnosis and initial treatment of
OSA in the VA to address this fundamental constraint in
current capacity using 4 different clinical approaches. Our
focus was on comparing the relative costs of each scenario
and the drivers of those costs. We maintained the perspec-
tive of the health-care system in the construction of the
economic model.
Methods
The methods consisted of 3 components (1) developing
a mathematical model depicting possible diagnostic and
treatment approaches to the care of patients with OSA,
(2) developing clinical scenarios to describe distinct
approaches to the management of patients with OSA,
and (3) identifying the costs associated with each of the
scenarios.
Model Construction
Model development involved constructing a flow model
describing components of a sleep medicine program and
identifying costs for each elements of the flow model.
Flow Model Development. The goal was to develop a
flow model that was comprehensive in terms of the diag-
nosis and treatment of OSA, including all possible ele-
ments of a sleep medicine program as it would be applied
to a patient with possible OSA. The clinical care of pa-
tients with non-OSA disorders (eg, narcolepsy) was out-
side of the scope of the project.
The flow model included elements and personnel re-
lated to the diagnosis of OSA and to the subsequent treat-
ment of patients with diagnosed OSA. The most com-
monly used and widely accepted procedure used to diagnose
OSA is polysomnography (PSG). PSG may be performed
in a sleep laboratory or in a non-laboratory setting and
may be attended or unattended. Laboratory-based PSG is
considered the accepted standard for OSA diagnosis.10,11
In-laboratory PSG involves having a patient spend the
night in a sleep laboratory, where a technician monitors the
patient using sensors that monitora broad range of sleep,
cardiovascular, and respiratory-related elements. If tech-
nicians detect OSA during the polysomnography, they may
apply a positive airway pressure (PAP) device to identify
the pressure at which the OSA is best treated; this proce-
dure is referred to as a split-night study. The results of a
PSG are reviewed by a scorer, and then a sleep medicine
physician reviews the scored results and makes treatment
and follow-up recommendations. The laboratory-based
PSG yields results that are highly accurate but requires a
sleep laboratory and significant personnel resources. Some
patients complain that they cannot sleep normally in the
unfamiliar and highly monitored environment of the sleep
laboratory, which may lead to a reduction in observed
hours of sleep during the in-laboratory PSG.12 Alternatives
to in-laboratory PSG include portable PSG, which is usu-
QUICK LOOK
Current knowledge
While OSA is a commonly recognized medical prob-
lem in the United States, a large majority of patients
with the condition remain undiagnosed. Because OSA
is associated with a variety of poor patient outcomes,
awareness of the importance of diagnosing OSA has
become much more common, with referrals for poly-
somnography sharply increasing over the past de-
cade. Sleep laboratory capacity has not accompanied
the dramatic increase in demand, contributing to wide-
spread under-diagnosis and under-treatment of OSA.
What this paper contributes to our knowledge
In a newly-developed mathematical model designed to
generate evidence-based cost estimates of 4 possible
diagnostic and treatment approaches to the care of pa-
tients with OSA (in-laboratory, unattended, direct-to-
auto-PAP, and mixed), the main driver of per-patient
costs was the total number of sleep studies, with this
total varying widely across scenarios. Approaches that
emphasized early application of auto-PAP had lower
per-patient costs.
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ally conducted in a patient’s home without overnight mon-
itoring by a technician and thus referred to as unattended.
Although the treatment of OSA includes behavioral rec-
ommendations (eg, weight loss), the cornerstone of ther-
apy involves the use of PAP while sleeping. PAP may be
applied using a fixed pressure setting or using autotitrating
settings. Fixed pressure PAP requires in-laboratory PAP
titration by a technician. Auto-titrating PAP (auto-PAP)
machines eliminate respiratory disturbances by varying the
pressure delivered, depending on the patients’ respiratory
efforts. Auto-PAP compared with fixed pressure PAP is
equally efficacious but is not appropriate for all patients
with OSA (eg, contraindicated for patients with congestive
heart failure).13-15 Auto-titrating PAP for treatment makes
it possible to shift the principal location for managing
OSA from the sleep laboratory to the patient’s home.
Members of the research team (NL and DMB) devel-
oped the initial flow model, which was then iteratively
revised in consultation with the VA Sleep Field Advisory
Committee. The committee determined the default staff
members for each patient contact (ie, whether a particular
patient contact should involve a nurse or a physician or a
respiratory therapist) and the average duration of each con-
tact. Figure 1 displays the final flow model. Each box
represents an episode of patient contact (eg, PAP initia-
tion). The diamond shapes indicate a decision point within
patient flow (eg, high residual apnea-hypopnea index [AHI]
with PAP). Two paths emanate from each diamond, a
“yes” and a “no” branch, based on the answer to the de-
cision question. This flow model resulted in a total of 23
combinations of diagnosis paths, including direct-to-auto-
PAP, unattended study, polysomnography, and in-lab titra-
tion possibilities.
Cost Allocations. The VA Office of Construction and
Facilities Management provided per square foot costs of
renovation and operating costs for facility space. The Of-
fice of Construction and Facilities Management periodi-
cally revises these cost data, which are used for planning
but not budgeting purposes. The economic model built for
this study included the cost of renovation, which was clas-
sified into three categories: light if renovation involved the
removal and replacement of up to approximately 30% of
the finishes and systems; medium if removal and replace-
ment of 31–67% of the existing space was indicated, and
total renovation if 67% removal and replacement was
required.
Sleep laboratories consist of rooms where patients sleep
and a monitoring station where the night sleep technician
observes the patients. One monitoring station (150 square
feet) can oversee up to 4 sleep study rooms of 210 square
feet each. To identify only the cost of patient care, the model
included the light renovationcostneeded for the recommended
number of sleep study rooms and associated monitoring sta-
tions at a rate of 4 study rooms to 1 monitoring station. We
included the cost of renovation as a startup cost, amortized
over 5 y. This analysis did not include the cost of exam-
ination rooms, because our baseline-case assumption was
that a facility already had adequate examination rooms. An
annual operating expense was included for the needed
sleep study and monitoring rooms at the local facility
rate specified by the Office of Construction and Facil-
ities Management.
Costs included in the per-patient costs included: startup
costs annualized over 5 y for the recommended sleep study
rooms; facility operating costs, depending on the amount
of facility space renovated; sleep medicine personnel in-
volved in patient care; and PSG supplies. We derived the
average cost of PSG supplies based on actual calendar-
year 2007 acquisition costs16 as follows: $234 for an un-
attended PSG, $200 for a full-night in-laboratory PSG, and
$305 for either an in-laboratory split-night or titration study.
Table 1 contains personnel costs for one full-time em-
ployee equivalent used in all scenario calculations. The
salaries included in the model were obtained from fiscal
year 2012 base pay rates, specifically the mid-point of the
starting salary range for staff at the Indianapolis VA fa-
cility. The Indiana facility was chosen because locality pay
for the Midwest is intermediate between the observed ex-
treme values (eg, highest in Northeast and California and
lowest in the South). The base pay amounts do not include
benefit pay or locality pay. Locality pay is used in the VA
to compensate staff in varying geographic regions. For
example, staff in the Northeast generally receive consid-
erably more locality pay than staff in the same position in
the South.
Table 2 displays the personnel and duration assigned to
each patient contact. The full-time employee equivalent
utilization rate was 85% to account for vacation, sickness,
education, and other reasons for time off. The staffing
costs were based on hiring only for the recommended
effort. For example, if a given scenario required 65% of
a physician, only 65% of the physician total costs
($223,626  0.65) were included in the analysis. In real-
ity, facilities are more likely to hire a 1.0 full-time em-
ployee equivalent physician in this situation and assign
that individual additional clinical duties. Rounding up in
this analysis was avoided because of its potential to ob-
scure differences between scenarios. Staffing costs were
based on the need for 0.25 full-time employee equivalent
for a physician to direct the sleep program and 1.00 full-
time employee equivalent for a sleep medicine nurse unit
manager. Polysomnographic scoring was included in the
analysis as requiring an initial review by a scorer (2 h per
in-laboratory PSG and 1 h per unattended study) and con-
firmation by a physician (1 h per in-laboratory PSG and
30 min per unattended study). PAP titration studies were
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included in the analysis as requiring 1 h of effort by the
scorer and 30 min of physician time.
Clinical Scenarios
We considered 4 scenarios for OSA diagnosis and treat-
ment to illustrate a wide variety of approaches to design-
ing a sleep medicine program. Our goal was to create
distinct approaches to the diagnosis and treatment of OSA
and then identify the key drivers of costs across these 4
scenarios. We sought to design relatively extreme scenar-
ios that may not represent current standard practice but
that illustrate how differences in sleep medicine program
design might influence costs.
All of the scenarios used the same set of baseline-case
assumptions, which drew upon recommendations of the
VA Field Advisory Committee as follows: 85% of patients
who were referred to a sleep medicine program would
have OSA (ie, the prevalence of OSA in the population
was 85%); 80% of unattended studies would have ade-
Fig. 1. Sleep Medicine Program flow chart. PSM  portable sleep monitoring, AHI  apnea-hypopnea index, OSA  obstructive sleep
apnea, PSG  polysomnography.
ECONOMIC ASSESSMENT OF OSA DIAGNOSIS AND TREATMENT
RESPIRATORY CARE • JANUARY 2018 VOL 63 NO 1 53
quate data for interpretation, with the remaining 20% re-
quiring an additional follow-up in-laboratory study; 100%
of patients with OSA would be referred for PAP; 100% of
patients with OSA receive a 20-min visit with a physician
to review the diagnosis and treatment options; 100% of
patients receiving CPAP have a 20-min visit with a day
sleep technician for mask fitting and habituation and then
a 20-min visit with a day sleep technician at 30 d postini-
tiation for troubleshooting and follow-up; 20% of patients
would have a contraindication to auto-PAP or a poor re-
sponse to auto-PAP (eg, high residual AHI on auto-PAP),
and these patients would require in-laboratory titration;
PAP devices that are provided to patients who do not
tolerate or use them are not refurbished for use by other
patients; and 40% of in-laboratory PSG patients who were
positive for OSA would have a split-night study that in-
cluded PAP titration. These rates are included in the flow
model depicting each scenario in Figures 2–5.
Scenario 1: In-Laboratory. The in-laboratory approach
(see Fig. 2) involves patients with suspected OSA receiv-
ing an in-laboratory PSG. Patients diagnosed with OSA
receive either a split-night study or a separate in-labora-
tory PAP titration. This approach does not use auto-PAP
or unattended PSG.
Scenario 2: Unattended. In the unattended approach,
the patient conducts the sleep study without monitoring by
a technician. Health-care organizations use 2 main strate-
gies for unattended polysomnography: sending staff to pa-
tients’ homes to set them up with the equipment or requir-
ing patients come to a facility for equipment and
instructions. Because the latter is the more common ap-
proach used in the VA, we modeled that scenario, employ-
ing type 3 portable sleep monitoring equipment. In the
unattended approach (see Fig. 3), patients with suspected
OSA go to a health-care facility, where they are set up for
a subsequent unattended, in-home PSG. Patients return
home, sleep using the equipment, and then mail it back to
the facility. Patients diagnosed with OSA are given auto-
PAP; some of these patients will have a poor response to
auto-PAP and will thus require in-laboratory CPAP titra-
tion. Patients who are negative for OSA are referred for
Table 1 Personnel Costs
Personnel BaseSalary
Total
Cost*
Required
Sleep physician (medical director, 0.25 FTEE) $150,000 $55,907
Nurse unit manager (1.00 FTEE) $65,000 $96,905
Variable time-allocated, depending on approach
Sleep medicine physician $150,000 $223,626
Sleep medicine nurse $65,000 $96,905
Night sleep technician $40,000 $59,634
Day respiratory therapist $55,000 $81,996
Polysomnography scorer $50,000 $74,542
Office assistant $35,000 $52,179
* Total costs include locality pay and 30% fringe-benefit cost.
FTEE  full-time employee equivalent
Table 2 Personnel Assignment for Each Activity
Activity Description Assigned Personnel Duration
Assessment of OSA probability Physician 20 min
Unattended PSG visit Day respiratory therapist 2 h
OSA clinic visit to discuss treatment options Physician 20 min
PAP initiation Day respiratory therapist 20 min
30-d auto-PAP follow-up Day respiratory therapist 20 min
Additional PAP follow-up visits (2) Registered nurse 20 min
Scoring of PSG Lab scorer 2 h
Physician 1 h
Scoring of unattended PSG Lab scorer 1 h
Physician 30 min
Scoring of titration studies Lab scorer 1 h
Physician 30 min
In-laboratory PSG Night sleep technician 8 h
In-laboratory PAP full-night titration Night sleep technician 8 h
In-laboratory split-night PAP titration Night sleep technician 4 h
The assignments refer to the type of person conducting an activity and the amount of time spent in each activity. The model could be modified as to whether or not any given activity was included
in the sleep medicine program design.
PSG  polysomnography
PAP  positive airway pressure
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in-laboratory PSG if clinical suspicion for OSA is high;
otherwise, no further PSG is needed. If patients do not
tolerate auto-PAP, they will receive in-laboratory CPAP
titration.
Scenario 3: Direct-to-Auto-PAP Approach. In the di-
rect-to-auto-PAP approach (see Fig. 4), patients with sus-
pected OSA and no obvious contraindications to auto-PAP
are given an auto-PAP machine and instruction on its use.
The physician may use screening tools, such as the Berlin
Questionnaire or the Sleep Apnea Clinical Score,17,18 dur-
ing the initial examination to identify suspected OSA. The
auto-PAP data are reviewed after a fixed period of time
(eg, 7 d) and considered positive based on elevations of the
residual AHI (ie, AHI  5 events/h) or the median pres-
sure (ie, 6 cm H2O); positive patients retain their ma-
chines and receive clinic follow-up.19,20 If the auto-PAP is
negative, then the patient is referred to in-laboratory PSG
with split-night titration if possible. If a patient has a poor
response to auto-PAP (eg, high residual AHI values), he or
she is referred for in-laboratory CPAP titration. Patients
suspected of having contraindications to auto-PAP are re-
ferred for an in-laboratory PSG. Because VA patients are
not subject to reimbursement requirements of the Centers
for Medicare and Medicaid Service or private insurance
companies, this approach is potentially feasible (albeit not
commonly used) in VA.
Scenario 4: Mixed Approach. In the mixed approach
(see Fig. 5), half of the patients with suspected OSA are
set up for unattended PSG and follow the course described
in the unattended approach, and the other half are referred
for in-laboratory testing and follow the in-laboratory ap-
proach. In practice, patients with a high probability of
OSA who live far away from a sleep laboratory or decline
to have an in-laboratory study would be candidates for
unattended PSG.
Model Interrogation to Identify Costs per Scenario
To demonstrate the economic effect of each of the sce-
narios, we created a hypothetical cohort of veterans
(N  1,000) who were referred to a VA sleep medicine
program for the purpose of screening and management of
OSA. We compared the estimated costs and timeline for
caring for the 1,000-patient cohort across the different sce-
narios. The scenarios differed in 2 values: the proportion of
patients who received PAP initially and the proportion of
patients who receive unattended studies. For example, in the
direct-to-auto-PAP approach, 100% of patients initially get
assigned to PAP. The same flow model applied across all
scenarios, with changes in the proportion of patients in the
hypothetical cohort of 1,000 patients who receive certain pro-
gram elements. The baseline assumption input values de-
scribed earlier were entered into the model to identify the
costs for each of the scenarios. The model identified the
facility space and personnel time needed for the 4 scenarios,
and these requirements were used to calculate costs. By com-
paring the model outputs for each of the 4 scenarios, we
identified key drivers of costs.
Results
The scenarios varied considerably in terms of the total
number of sleep studies that were ultimately required by
each approach, ranging from 425 for direct-to-auto-PAP to
Fig. 2. In-laboratory approach.
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1,441 for unattended (see Table 3). The number of sleep
studies drove staffing costs because of the need to score
and review studies, which applies to both unattended and
in-laboratory PSGs. The lowest personnel costs were ob-
served for the direct-to-auto-PAP approach. Personnel costs
for the other 3 approaches were relatively similar and ap-
proximately 2 times higher than those for the direct-to-
auto-PAP approach. The number of sleep studies also drove
supply costs, which were lowest for direct-to-auto-PAP
and highest for unattended ($99,287 vs $351,027 for the
1,000-patient cohort; see Table 3).
Table 3 also shows the number of additional rooms
needed for each scenario. The in-laboratory approach fa-
cility cost was highest, almost 3 times the facility cost of
the direct-to-auto-PAP and unattended approaches.
Per-patient costs differed by scenario: $456 for the di-
rect-to-auto-PAP approach, $913 for the in-laboratory ap-
proach, $991 for the mixed approach, and $1,090 for the
unattended approach, excluding facility startup costs. Ap-
pendix A (see the supplementary materials at http://
www.rcjournal.com) provides a flow diagram for an ap-
proach that minimized cost per patient.
Table 4 displays the cost results of varying the success
rate of unattended studies (ie, the proportion of studies
with data of sufficient quality to score the study) from 50
to 100%. The cost per patient ranged from $973 for the
extremely optimistic case, where 100% of unattended stud-
ies produced excellent data sufficient for scoring, to $1,261
for the extremely pessimistic case of data failure in 50% of
unattended studies. There was less per-patient cost vari-
ability within the range of more typically reported values
of 80–95% data success (see Table 4).
Discussion
The in-laboratory, unattended, and direct-to-auto-PAP
approaches represent a wide variety of configurations for
sleep medicine programs. Comparison across these sce-
narios provided insights into differential costs across ap-
proaches as well as key drivers of those costs. Model
results indicated that drivers of per-patient cost were per-
sonnel costs and facility operations costs related to both
the number and type of PSGs (attended vs unattended).
The direct-to-auto-PAP approach had the lowest cost per
Fig. 3. Unattended approach.
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patient ($590), and the in-laboratory approach had the high-
est cost per patient ($1,418) when facility startup costs
were included. The in-laboratory approach required fewer
PSGs overall than the unattended or mixed scenarios, but
the in-laboratory PSGs were more expensive than the un-
attended PSGs.
Our findings illustrate the importance of explicitly spec-
ifying and considering various facility costs in economic
evaluations of health-care programs. For example, the in-
laboratory approach was less expensive than either the
mixed or unattended approaches when facility startup costs
were excluded, but it was more expensive than both of these
approaches when facility costs were included. Prior economic
evaluations regarding alternative approaches to the diagnosis
of patients with OSA have generally compared 2 or more
approaches from a per-patient perspective and have not con-
sidered facility-level costs.21,22 They have all found that the
per-patient costs (or charges) for in-laboratory PSG were
higher than for in-home PSG21-23; however, the differ-
ences in costs vary from approximately 20%22,23 to 400%21
increase over the in-home cost. Kim et al23 included an
assessment of the provider perspective in their cost anal-
ysis, which included labor costs, supplies, equipment, and
facility rental costs. They found that an in-laboratory ap-
proach was 13% more expensive than an in-home ap-
proach ($1,809 vs $1,599) when only patient costs (in an
analysis the authors referred to as the payer perspective)
were included but that the in-laboratory approach was 2%
less expensive than an in-home approach when facility
costs were included ($1,697 vs $1,736; an analysis the
authors referred to as the provider perspective).23 The find-
ing by Kim et al23 similarly indicates the importance of
considering facility costs in the economic assessment of
alternative diagnostic approaches, but it is in the opposite
direction from our finding. The Kim et al study23 was
based on a randomized controlled trial and observed that
41% of the subjects who were randomized to the in-home
group required in-laboratory PSG; this is twice the rate
used in our model.23 The rate used in the current study was
based on expert opinion and reflected the current clinical
experience of VA sleep medicine physicians who have
experience with the application of unattended polysom-
nography in patients’ homes.
In addition to the focus on including facility costs and
the facility perspective, the current study advances the
existing literature by including a greater spectrum of al-
ternative sleep medicine program configurations than the
prior studies. Specifically, the inclusion of a direct-to-
auto-PAP approach and the mixed approach is, to our
knowledge, a novel contribution. Our objective in design-
ing the clinical scenarios was to provide a wide range of
alternatives to identify cost differences and drivers, not to
promote any particular clinical approach. The majority of
sleep medicine programs in the United States do not cur-
rently employ a direct-to-auto-PAP approach. In-labora-
tory PSG provides diagnostic information that may be of
importance to the care of an individual patient (eg, peri-
odic limb movements) and may be indicated for patients
when the clinical question extends beyond simply making
or excluding the diagnosis of OSA. Given an OSA prev-
alence of 85% for most VA sleep medicine programs,
however, the direct-to-auto-PAP approach may provide
Fig. 4. Direct-to-auto-PAP approach.
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treatment to patients with minimal delay and lowest over-
all cost for the large majority of patients who will require
PAP therapy. The direct-to-auto-PAP approach may also
represent the most convenient option to patients, given the
reduced need for polysomnography. The direct-to-auto-
PAP and unattended approaches merit further attention in
an era of patient-centered care that seeks to move more
types of care from medical centers to where the patient
lives.
The unattended approach resulted in the greatest num-
ber of total PSGs for 2 reasons. First, split-night studies
are not possible during unattended PSG. Second, as rec-
ommended by our external expert panel, we estimated that
20% of the unattended PSGs would result in unusable
data, triggering the need for a subsequent in-laboratory
PSG.
Several published studies have used an unattended ap-
proach, most notably the Heart Health Study, with excel-
lent results in terms of validity and reliability.16,24,25 Stud-
ies have reported good to excellent agreement between
unattended PSG and laboratory-based PSG (sensitivities,
75–100%; specificities, 87–100%).26-28 Moreover, some
authors have argued that in-home PSGs provide enhanced
data when compared with in-laboratory studies because
patients feel comfortable sleeping in their own homes,
whereas in a sleep laboratory they must acclimatize to an
unfamiliar setting, resulting in fewer hours of reliable sleep
data.12
Unattended PSG is increasingly recognized by national
professional organizations. Both the Portable Monitoring
Task Force of the American Academy of Sleep Medicine
and the VA Sleep-Related Breathing Disorders Source
Book refer to unattended PSG as an acceptable alternative
when patients cannot accommodate a laboratory-based
PSG.10,11 The American Academy of Sleep Medicine, in
their 2007 Portable Monitoring Task Force Report, rec-
ommended the use of portable monitoring when performed
under the direction of a certified sleep medicine program
for patients with a high likelihood of moderate to severe
OSA.11 Unattended polysomnography has not yet been
Fig. 5. Mixed approach.
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universally adopted in routine clinical practice and may
represent a viable approach for many health-care organi-
zations seeking to address unmet demand for diagnosing
and treating OSA in a cost-sensitive way. Within the VA,
facilities with limited sleep laboratory resources most com-
monly outsource PSGs to non-VA facilities via a “fee-
basis” mechanism, with these fee-basis studies almost ex-
clusively consisting of in-laboratory PSGs.
It may be that a single approach to the diagnosis of OSA
does not adequately meet the needs of a population served
by a given sleep medicine program, especially if the pop-
ulation is diverse in terms of access to a sleep laboratory or
preferences about in-home versus in-laboratory testing. The
mixed approach provides one relevant scenario of a config-
uration that allows for local tailoring of sleep medicine ser-
vices. The mixed approach had per-patient costs that fell
between the unattended and in-laboratory approaches. The
VA provides an ideal setting in which to develop a tailored
sleep medicine approach for several reasons. First, OSA is
common among veterans. Second, the VA electronic medical
record facilitates both the identification of patients at increased
risk of having OSA and communication with primary care
providers about sleep medicine recommendations. Third, the
VA has relatively few financial barriers for patients to receive
care. Fourth, unlike the private sector, which receives less
reimbursement from insurance and Medicaid/Medicare for
portable monitoring than for in-laboratory polysomnography,
practice of care within the VA is less sensitive to third-
party reimbursement policies.
Attended polysomnography performed in a sleep labo-
ratory remains the accepted standard for diagnosing OSA.
There are major barriers, however, associated with scaling
up its use to meet current demand. Within the VA, poly-
somnography may have a long wait time even when using
non-VA sleep laboratories under the fee-basis mechanism.
Model results indicated that time to treatment initiation
was similar for the direct-to-auto-PAP and the unattended
approach, twice as long for the mixed approach, and 3
times as long for the in-laboratory approach. Veterans in
rural areas often must travel significant distances to the
nearest sleep laboratory (VA or non-VA). For some pa-
tients, especially those who are caregivers to others, the
requirement to stay away from home prevents them from
completing an in-laboratory study.
The strength of this study was that the flow model eval-
uated the relative costs of 4 different configurations of
sleep services. Although supply cost estimates were ob-
tained from private-sector United States sources, limita-
tions of this analysis included that personnel and renova-
tion data were all obtained from VA sources and that
neither the cost of CPAP machines nor the postage costs
for patients to return unattended PSG equipment back to
the facility were included in the model. Estimated per-
patient costs may thus not generalize to non-VA settings,
although the relative differences in costs across scenarios
and the key drivers of those costs should still apply. Sim-
ilarly, because we used salary estimates from Indiana, the
estimated per-patient costs are expected to be an overes-
timate for VA sites with lower locality pay (eg, the South)
and an underestimate for VA sites with higher locality pay
(eg, New England); however, relative cost differences are
again expected to be generalizable. The expenses for unat-
tended polysomnography could be lower than the costs used
in this study if equipment is obtained at discounted rates from
manufacturers (ie, bulk orders from large health-care sys-
tems) and if other cost-saving strategies are used (eg, group
visits to instruct many patients in the use of the equipment
instead of individual patient instruction). We did not model
potential differences in adherence to PAP therapy that may
be due to differences in the diagnosis method (eg, patients
diagnosed via a direct-to-auto-PAP approach may be less
likely to be convinced of their diagnosis of OSA and thereby
less inclined to be diligent with PAP therapy) because data
regarding the existence or strength of such disparities is cur-
rently lacking. Finally, the assumptions used to construct the
flow diagrams were based on expert opinion. Therefore, we
have been explicit about the assumptions that were included
in the study, and although we conducted sensitivity analyses
Table 4 Cost Sensitivity to the Rate of Success of Unattended Polysomnography
Item
Success Rate of Unattended Polysomnography
50% 80%* 95% 100%
Facility operations $31,000 $24,000 $24,000 $24,000
Personnel $826,000 $715,000 $654,000 $633,000
Supplies $404,000 $351,000 $325,000 $316,000
Clinic hours 3,360 3,192 3,108 3,080
Total No. of sleep studies 1,690 1,437 1,313 1,270
Home/Laboratory/Titrations 1,000/388/301 1,000/155/282 1,000/39/273 1,000/0/270
Cost/patient $1,261 $1,090 $1,003 $973
* 80% was the value used as the baseline-case assumption.
ECONOMIC ASSESSMENT OF OSA DIAGNOSIS AND TREATMENT
60 RESPIRATORY CARE • JANUARY 2018 VOL 63 NO 1
related to the performance of the unattended PSGs, other
sensitivity analyses could be conducted (eg, changes in the
prevalence of OSA).
Conclusions
Demand for sleep studies far outstrips capacity in tra-
ditional facility-based sleep laboratories. Different ap-
proaches to diagnosing and treating OSA carry different
costs, and this model of 4 different approaches indicated
that approaches emphasizing early application of auto-PAP
resulted in lower per-patient costs. These findings can as-
sist health-care organizations in assessing tradeoffs and
costs when developing their own approaches to addressing
unmet needs for diagnosing and treating OSA among their
own patient populations.
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